Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24.
Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback